CellSource CoTSE:4880 -2.15%69 Gross Margin % is 58.84% as of Apr. 2026, which is 17% below its 10-year median of 70.61. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 730 Biotechnology companies, CellSource Co ranks worse than 53.42% on this metric.
CellSource Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -4.7%.
The historical rank and industry rank for CellSource Co's Gross Margin % or its related term are showing as below:
TSE:4880'
s Gross Margin % Range Over the Past 10 Years
Min: 55.51 Med: 70.61 Max: 72.23
Current: 57.57
During the past 9 years, the highestGross Margin % of CellSource Co was 72.23%. The lowest was 55.51%. And the median was 70.61%.
TSE:4880's Gross Margin % is ranked worse than 53.42% of 730
companies
in the Biotechnology industry
Industry Median: 60.91
vs TSE:4880: 57.57
CellSource Co had a gross margin of 58.84% for the quarter that ended in Apr. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for CellSource Co was -4.70% per year.
CellSource Co (TSE:4880) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CellSource Co had a gross margin of 58.84% for the quarter that ended in Apr. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CellSource Co Gross Margin % Related Terms
CellSource Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for CellSource Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, CellSource Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CellSource Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CellSource Co (TSE:4880) has a Gross Margin % of 58.84% as of Apr. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on CellSource Co and its competitors. This is 17% below median its historical median of 70.61. Over the past decade, CellSource Co's Gross Margin % has ranged from 55.51 to 72.23. According to the industry distribution chart, CellSource Co ranks #390 out of 730 companies in the Biotechnology industry, placing it in the top 53.4%.
Is CellSource Co's Gross Margin % too high?
CellSource Co's current Gross Margin % of 58.84% is 17% below median its 10-year median of 70.61. Over the past 10 years, this metric has ranged from a low of 55.51 to a high of 72.23. The Biotechnology industry median Gross Margin % is 60.91. CellSource Co's value of 58.84% is 3.4% below this industry median. Based on the distribution chart, CellSource Co ranks #390 out of 730 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #390 out of 730 companies for Gross Margin %. This places CellSource Co in the lower half of its industry. The industry median Gross Margin % is 60.91. CellSource Co's value of 58.84% is 3.4% below this benchmark. Historically, CellSource Co's own Gross Margin % has ranged from 55.51 to 72.23 over the past decade. While the company's 10-year median is 70.61 vs. the industry median of 60.91, CellSource Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current Gross Margin % of 58.84% is 3.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CellSource Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current Gross Margin % is 58.84%, which is 17% below median its own 10-year median of 70.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current Gross Margin % is 58.84%, which is 17% below median its 10-year median of 70.61 and 3.4% below the Biotechnology industry median of 60.91. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Gross Margin % is 58.84% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
Gross Margin %: 58.84% (17% below median its 10-year median of 70.61)
GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
Industry Position: 3.4% below the Biotechnology median (#390 of 730)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
